


DeLLphi-304 Study in Small Cell Lung Cancer (SCLC)

A Phase 3 clinical study comparing tarlatamab with standard of care chemotherapy in patients whose cancer has returned after first-line treatment.

ClinicalTrials.gov Number: NCT05740566




TarlatamabClinicalTrials.com



About This Clinical Study

What is tarlatamab?

Tarlatamab is an investigational study drug called a bispecific T-cell engager, or BiTE[®] molecule, that has two key parts: **a part that attaches to your T-cells, a type of immune cell, and a part that attaches to the cancer cells.**



Tarlatamab is a type of immunotherapy that works differently than standard chemotherapy. It is designed to help the body's immune cells find, attach to, and attack cancer cells.

What is the DeLLphi-304 study?

DeLLphi-304 is a Phase 3 clinical study comparing tarlatamab with standard of care chemotherapy in patients whose cancer has returned after first-line treatment. Participants will be randomly assigned to receive the treatment they would normally receive (standard of care chemotherapy) or the study drug, tarlatamab.)

Who is able to join the DeLLphi-304 study?

Clinical studies have strict rules. This protects people who join the study and ensures that the results of the study can be trusted. Your doctor can help you decide if this study is right for you by reviewing the rules and your health history.


You may be able to join DeLLphi-304 if you are at least 18 years old and have:

- ✓ SCLC that has returned after first-line treatment
- ✓ Received a platinum-based chemotherapy
- ✓ Tumor(s) that can be seen on imaging

Study participants must also meet additional eligibility criteria.

For more information about eligibility criteria, please speak to your healthcare team or call Amgen Medical Information at 1-800-772-6434 (1-800-77-AMGEN).

For physicians



ClinicalTrials.gov
Number:
NCT05740566